Antibody Drug Conjugate Market Review
The antibody drug conjugate market 2020 can achieve an approximate growth rate of 19% over the forecast period (between 2017 and 2023), suggests MRFR (Market Research Future). We will provide COVID-19 impact analysis with the report, along with an in-depth review post the coronavirus disease outbreak.
COVID-19 Impact on Antibody Drug Conjugate Market
With the COVID-19 outbreak and the growing cases worldwide, patients are requiring mechanical ventilation and intensive monitoring, overwhelming the healthcare industry. Overloaded hospitals are not able to actively cater to the cancer patients, who form a highly vulnerable and fragile population base in the world, and the outcome of this situation is expected to be unfavorable for the antibody drug conjugate market. The soaring SARS-CoV-2 cases and the subsequent lockdown have resulted in travel restrictions, which have been particularly hard for people in remote areas, while the sequestering of the hospital staff has promoted the adoption of telephone or online consultation, while critical tests, procedures and therapy have been deferred.
The pandemic has had a detrimental impact on drug development timelines, with monetary implications on pharma companies. However, since studies show that patients with lymphoma and leukemia are at a high risk of contracting the novel coronavirus, the antibody drug conjugate market can observe sustained demand in the near future.
Browse Complete Report: https://www.marketresearchfuture.com/sample_request/1113
Top Boosters and Deterrents
Significant technological innovations are instrumental in the market growth across the world. Other than that, the escalating cancer cases, especially among the expanding geriatric populace can bolster the demand for antibody drug conjugate (ADC). The World Health Organization/WHO confirms that individuals beyond the age of 65 years will account for 16% of the global population by 2050, jumping from 7% in the year 2000. Aging is a major factor that increases the risk of several diseases, one of them being cancer. Therefore, the antibody drug conjugate market potential in the following years will be bolstered by the burgeoning elderly population worldwide.
Up until 2017, Kadcyla by Roche and Adcetris by Seattle Genetics were the only two commercial ADCs available in the market. But recently, Pfizer’s two products were given the approval for being marketed, targeting acute lymphoblastic leukemia and acute myeloid leukemia. Thus, it is expected that during the evaluation period, Pfizer could emerge as one of the top market leaders. Besides, the ongoing developments in the medical technology, preclinical researches on antibody therapies, novel drug discoveries and the overall surge in researches that are based on oncology diseases are projected to benefit the global market.
Rise in collaborations and partnerships between biotechnology firms, biopharmaceuticals and research institutes is fuelling the market growth and can significantly boost the demand for antibody drug conjugates in the long terms. Many of the top vendors are also introducing superior quality products, adopting production expansions and acquisitions as growth strategies to foster their global presence. To illustrate, in October 2020, Merck acquired Seagen in a deal valued at USD 1 billion. This move is considered to be a continuation of the agreement between both the companies to create ladiratuzumab vedotin and various other antibody-drug conjugates.
Request Free Sample:https://www.marketresearchfuture.com/reports/antibody-drug-conjugate-market-1113
Market Segmentation
Antibody drug conjugate market size has been evaluated in the MRFR report, while considering type, product, technology, application, and end-user as the key segments.
The key types of antibody drug conjugates in the market are drug/toxin, linker, monoclonal antibodies, and others.
Applications considered in the report are breast cancer, lung cancer, prostate cancer, pancreas cancer, multiple myeloma, skin cancer, kidney cancer, ovary cancer, colon cancer, leukemia, solid tumors, glioblastoma, lymphoma, and others.
Product-wise, the market segments include Kadcyla, Adcertis, and others.
Technologies analyzed in the report are Immunomedics technology, Seattle Genetics technology, ImmunoGen technology, and others.
Biotechnology companies, academic research institutes, specialized cancer centers, biopharmaceutical companies, hospitals, and others are the top end-users in the worldwide market.
Regional Insight
Antibody drug conjugate market growth trends have been studied extensively in the report, keeping in mind certain regions, namely America, Asia Pacific, MEA or Middle East and Africa and Europe.
The American market is the global leader and can remain so throughout the conjectured period, given the dramatic surge in cancer cases and the high prevalence of unhealthy lifestyle among the urban population. The rising consumption of alcohol and tobacco and the rampant demand for quality and cost-effective cancer treatment and drugs also add to the revenue generation in the region. High obesity rate and the frequent researches carried out to study oncology diseases also benefit the American market. Other factors that bolster the antibody drug conjugate market size in the region include the massive investments by biotechnology and pharmaceutical vendors. The most profitable market in the region is the US, while Mexico and Canada are emerging at a rapid pace as well.
APAC is one of the fastest developing markets as many consumers are fast gaining knowledge about these drugs, with the rising number of government initiatives turning out to be a helpful factor. The significant number of products in the pipeline and the expanding pool of Biopharmaceutical and Biotechnology vendors are also enhancing the antibody drug conjugate market potential in the region.
Top Companies
Celldex Therapeutics (US), Roche Holding AG (Switzerland), Oxford BioTherapeutics (US), Antikor (UK), ImmunoGen, Inc. (US), Immunomedics (US), AbbVie Inc. (US), Millennium Pharmaceuticals (US), Genentech (US), Astellas Pharma/Agensys (Japan), Synthon (US), Heidelberg Pharma (Germany), Mersana Therapeutics (US), Agensys, Inc. (US), Bayer HealthCare (Germany), Seattle Genetics (US), Progenics Pharmaceuticals (US), Concortis Biotherapeutics (US), Pfizer Inc. (US), are the top companies that are actively seeking out techniques to bolster their market position.